A 4-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 evolution and recovery in non-hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500244-37-00

Acronym

KIN001-204

Enrollment

150

Registered

2022-08-03

Start date

2022-08-25

Completion date

2025-04-24

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Number of days alive with no score > 1 in each of the symptoms and a maximum of 3 points in the total score, measured from inclusion to day 28

Detailed description

Time to recovery, based on patient-reported daily evaluation of symptoms, All-cause unplanned hospital admission for at least 24 hours or death by day 28, Total sum of daily score of symptoms from inclusion to day 28, Number of days with no symptoms scoring > 1 from inclusion today 14 and day 28, Proportion of patients with full recovery at day 14 and day 28 (no more than 3 items scoring > 1), Inflammatory markers values at day 14 (hsCRP), Safety and tolerability of pamapimod used in combination with pioglitazone (AEs, SAEs), Number of family members (same household) testing positive by rtPCR test within 2 to 10 days after inclusion

Interventions

DRUGPioglitazone Placebo

DRUGPamapimod Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of days alive with no score > 1 in each of the symptoms and a maximum of 3 points in the total score, measured from inclusion to day 28	—

Secondary

Measure	Time frame
Time to recovery, based on patient-reported daily evaluation of symptoms, All-cause unplanned hospital admission for at least 24 hours or death by day 28, Total sum of daily score of symptoms from inclusion to day 28, Number of days with no symptoms scoring > 1 from inclusion today 14 and day 28, Proportion of patients with full recovery at day 14 and day 28 (no more than 3 items scoring > 1), Inflammatory markers values at day 14 (hsCRP), Safety and tolerability of pamapimod used in combination with pioglitazone (AEs, SAEs), Number of family members (same household) testing positive by rtPCR test within 2 to 10 days after inclusion	—

Measure

Time frame

—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026